98%
921
2 minutes
20
Objective: Decision-making is impaired in patients with epilepsy; however, the changes in decision-making in patients with new-onset and seizure-remission epilepsy remain unclear. The aim of this study was to examine decision-making differences in patients with new-onset and seizure-remission epilepsy, as well as the neurophysiological mechanisms.
Methods: This study included 32 patients with new-onset epilepsy, 31 with seizure-remission epilepsy with generalized tonic-clonic seizures, and 34 matched healthy individuals. Simultaneous electroencephalogram was performed using the Iowa gambling task (IGT). Behavioral performance in the IGT was assessed among the three groups, and P300 and theta oscillations were used as electrophysiological indicators to observe decision-making ability.
Results: Patients with new-onset and seizure-remission epilepsy had significantly lower net scores, lower accounts, and lesser P300 amplitudes and theta oscillation power than did healthy individuals. The percent use of negative feedback was positively correlated with the P300 amplitude.
Conclusion: Impaired decision-making in persons with epilepsy is associated with decreased P300 amplitude and attenuated theta oscillations. Decision-making function was impaired despite clinical seizure-remission.
Significance: This study is the first to compare the behavioral differences in decision-making ability between patients with new-onset and seizure-remission epilepsy. The combination of electroencephalographic features reveals neural mechanisms and improves the understanding of epilepsy decision-making.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363282 | PMC |
http://dx.doi.org/10.3389/fnins.2025.1644485 | DOI Listing |
Eur J Case Rep Intern Med
August 2025
Charleston Area Medical Center, Charleston, USA.
Introduction: species, particularly , are rare opportunistic pathogens that typically affect immunocompromised individuals. These infections usually present with respiratory or systemic symptoms and are often linked to environmental exposure. Asymptomatic infections are exceedingly rare and pose unique diagnostic and therapeutic challenges.
View Article and Find Full Text PDFEur J Case Rep Intern Med
August 2025
Department of Internal Medicine, Local Health Unit of São João, Porto, Portugal.
Unlabelled: Bariatric surgery has emerged as a highly effective treatment option for individuals with obesity. Severe hypoalbuminaemia is a feared complication after a Roux-en-Y gastric bypass. It is characterised by a low serum albumin level of <25 g/l, neither explained by renal losses, protein-losing enteropathy nor by liver disfunction, and is associated with high morbidity and mortality.
View Article and Find Full Text PDFNutr Metab Cardiovasc Dis
August 2025
Department of Cardiology, Kailuan Hospital, Tangshan, China. Electronic address:
Background And Aims: Diabetes mellitus (DM) commonly coexists with non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD), and when combined with these two conditions, the risk of all-cause mortality and developing cardiovascular diseases (CVD) increases. The present community-based cohort study aimed to elucidate the combined effect of NAFLD and CKD on CVD and mortality risks in new-onset DM patients.
Methods And Results: After the exclusion of participants failing to meet the inclusion criteria, 11,328 eligible participants (mean age: 58.
Hepatology
September 2025
Department of Gastroenterology and Hepatology, UT Southwestern, Dallas, TX.
Background: The clinical course and outcomes of alcohol-associated hepatitis (AH) remain poorly understood. Major adverse liver outcomes (MALO) do not capture the added risk of return to drinking (RTD). We examined the natural history of AH and developed a composite endpoint using a contemporary observational cohort of AH.
View Article and Find Full Text PDFJ Neurooncol
September 2025
Department of Brain and Neurosciences, Division of Neurosurgery, Faculty of Medicine, Tottori University, Tottori, Japan.
Introduction: Hypertension, the most common adverse events associated with bevacizumab (BEV) treatment, has been proposed as a potential biomarker of treatment response in glioblastoma (GBM) patients. This study aimed to evaluate whether the timing of hypertension serves as a prognostic value in GBM patients.
Methods: This retrospective study consisting of 56 GBM patients treated with initial BEV between 2013 and 2024.